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Bethesda, Maryland; Department of Health Economics and Policy, London School of Hygiene and Tropical Medicine,
London, United Kingdom
Abstract. Each year, up to three million deaths due to malaria and close to five billion episodes of clinical illness
possibly meriting antimalarial therapy occur throughout the world, with Africa having more than 90% of this burden.
Almost 3% of disability adjusted life years are due to malaria mortality globally, 10% in Africa. New information is
presented in this supplement on malaria-related perinatal mortality, occurrence of human immunodeficiency virus in
pregnancy, undernutrition, and neurologic, cognitive, and developmental sequelae. The entomologic determinants of
transmission and uses of modeling for program planning and disease prediction and prevention are discussed. New data
are presented from the Democratic Republic of the Congo, Tanzania, Ethiopia, and Zimbabwe on the increasing urban
malaria problem and on epidemic malaria. Between 6% and 28% of the malaria burden may occur in cities, which
comprise less than 2% of the African surface. Macroeconomic projections show that the costs are far greater than the
costs of individual cases, with a substantial deleterious impact of malaria on schooling of patients, external investments
into endemic countries, and tourism. Poor populations are at greatest risk; 58% of the cases occur in the poorest 20%
of the world’s population and these patients receive the worst care and have catastrophic economic consequences from
their illness. This social vulnerability requires better understanding for improving deployment, access, quality, and use
of effective interventions. Studies from Ghana and elsewhere indicate that for every patient with febrile illness assumed
to be malaria seen in health facilities, 4−5 episodes occur in the community. Effective actions for malaria control
mandate rational public policies; market forces, which often drive sales and use of drugs and other interventions, are
unlikely to guarantee their use. Artemisinin-based combination therapy (ACT) for malaria is rapidly gaining acceptance
as an effective approach for countering the spread and intensity of Plasmodium falciparum resistance to chloroquine,
sulfadoxine/pyrimethamine, and other antimalarial drugs. Although costly, ACT ($1.20−2.50 per adult treatment) be-
comes more cost-effective as resistance to alternative drugs increases; early use of ACT may delay development of
resistance to these drugs and prevent the medical toll associated with use of ineffective drugs.
The burden of malaria in one district in Tanzania has not decreased since the primary health care approach replaced
the vertical malaria control efforts of the 1960s. Despite decentralization, this situation resulted, in part, from weak
district management capacity, poor coordination, inadequate monitoring, and lack of training of key staff. Experience
in the Solomon Islands showed that spraying with DDT, use of insecticide-treated bed nets (ITNs), and health education
were all associated with disease reduction. The use of nets permitted a reduction in DDT spraying, but could not replace
it without an increased malaria incidence. Baseline data and reliable monitoring of key outcome indicators are needed
to measure whether the ambitious goals for the control of malaria and other diseases has occurred. Such systems are
being used for evidence-based decision making in Tanzania and several other countries. Baseline cluster sampling
surveys in several countries across Africa indicate that only 53% of the children with febrile illness in malarious areas
are being treated; chloroquine (CQ) is used 84% of the time, even where the drug may be ineffective. Insecticide-treated
bed nets were used only 2% of the time by children less than five years of age. Progress in malaria vaccine research has
been substantial over the past five years; 35 candidate malaria vaccines are in development, many of which are in clinical
trials. Development of new vaccines and drugs has been the result of increased investments and formation of public-
private partnerships. Before malaria vaccine becomes deployed, consideration must be given to disease burden, cost-
effectiveness, financing, delivery systems, and approval by regulatory agencies. Key to evaluation of vaccine effective-
ness will be collection and prompt analysis of epidemiologic information. Training of persons in every aspect of malaria
research and control is essential for programs to succeed. The Multilateral Initiative on Malaria (MIM) is actively
promoting research capacity strengthening and has established networks of institutions and scientists throughout the
African continent, most of whom are now linked by modern information-sharing networks. Evidence over the past
century is that successful control malaria programs have been linked to strong research activities. To ensure effective
coordination and cooperation between the growing number of research and control coalitions forming in support of
malaria activities, an umbrella group is needed. With continued support for scientists and control workers globally,
particularly in low-income malarious countries, the long-deferred dream of malaria elimination can become a reality.
INTRODUCTION
“Ex Africa semper aliquid novi”
(“There is always something new coming out of Africa”)
Gaius Plinius Secundus (Pliny the Elder), AD 23−79
There has been rapidly increasing optimism for greatly im-
proved malaria control, particularly in Africa where the vast
majority of people affected by the disease reside (Figure 1).
This new positive attitude is based on major advances in ma-
laria research and public health practices, and careful epide-
miologic and economic analyses of malaria’s burden and cost-
effective ways to lessen it. Most crucial has been heretofore
unheard of political, strategic, and financial support for ma-
laria scientific studies and control actions. The support has
come from a variety of recently formed coalitions—from the
scientific and policy-making communities in countries most
affected by the disease, by formation of public-private part-
nerships to develop new drugs and vaccines, from national
and international organizations that had not traditionally sup-
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ported malaria work, from foundations such as the Wellcome
Trust, with a long history of malaria research support, and
those more recently committed to malaria research, opera-
tions, and training such as the Fogarty International Center,
National Institutes of Health (NIH), the Howard Hughes
Medical Institute, the Ellison Foundation, the United Nations
Children’s Fund (UNICEF), the European Commission, and
the Bill & Melinda Gates Foundation. The Global Fund for
human immunodeficiency virus/acquired immunodeficiency
virus (HIV/AIDS), Tuberculosis and Malaria (Global Fund),
the MIM, the Medicines for Malaria Venture (MMV), the
Malaria Vaccine Initiative (MVI), the African Malaria Net-
work Trust (AMANET), the Gates Malaria Partnership
based at the London School of Hygiene and Tropical Medi-
cine, and the Malaria Research Institute at the Johns Hopkins
University Bloomberg School of Public Health are just a few
of the new initiatives focusing on malaria that bring added
perspective, innovation, energy, and resources to the growing
malaria-related budgets and programs. Major growth in ma-
laria research and control programs has also occurred in or-
ganizations with a long commitment to malaria work–the Na-
tional Institute of Allergy and Infectious Diseases (NIAID,
NIH), Centers for Disease Control and Prevention (CDC),
U.S. Agency for International Development (USAID),
World Health Organization (WHO), and many other organi-
zations. A resounding call for more efforts to better under-
stand and control malaria came from representatives of 44 of
the 50 African malarious countries who met in Abuja, Nige-
ria, in 2000 and vowed to bring national and international
attention and resources to battle this perennial peril.1
The Third MIM Pan-African Conference on Malaria was
held in Arusha, Tanzania on November 18−22, 2002 with the
theme “Global Advances in Malaria Research: Evidence-
Based Decision Making for Malaria Control and Policy.” At
the Conference, an all-day symposium was held on “The In-
tolerable Burden of Malaria: What’s New, What’s Needed.”
There were 18 speakers who addressed new insights from
clinical, epidemiologic, immunologic, entomologic, public
health, economic, and public policy research. Selected papers
from this symposium, and others subsequently invited, have
been assembled in this second supplement to the American
Journal of Tropical Medicine and Hygiene devoted to high-
lighting the “intolerable burden of malaria”. The first supple-
ment, published in 2001, focused mainly on defining the clini-
cal and epidemiologic burden and its components.2 These
articles, summarized here, go beyond the first edition by ad-
dressing newer findings. The goal, once again, is to promote
research by African scientists and colleagues elsewhere to
improve our understanding of malaria, develop new tools to
combat it, and, ultimately, eliminate this scourge.
BURDEN
Morbidity, mortality, and disability from malaria (and
other diseases) are now being summarized in a new metric,
disability-adjusted life years (DALYs), an aggregate measure
of premature mortality, morbidity, and disability, which can
also be used for analyzing cost-effectiveness of the major in-
terventions.3 The WHO calculates the burden of malaria and
other diseases based on an assessment of global DALYs, with
apportionment of each disease contribution based on selected
epidemiologic data and estimates from field studies. This ap-
proach does not lend itself to reflecting uncertainty ranges
and, for malaria, the burdens resulting from the many clinical
manifestations of disease, some of which are still being de-
fined.4–6 Tables 1 and 2 show the global burden of malaria
mortality and DALYs derived from deaths reported by the
WHO.7 The African continent shows the greatest effects of
this disease, accounting for more than 90% of the burden,
including African countries in the Eastern Mediterranean Re-
gion of WHO, followed by Southeast Asia with almost 9% of
the burden. Malaria deaths are responsible for almost 3% of
the world’s DALYs (> 10% in Africa), not counting the con-
siderable and imprecisely quantified burden due to morbidity
and disability. Despite advances in understanding malaria
ecology, and development of interventions, more than 50% of
the world’s population is exposed to malaria. This is an in-
crease of close to 10% over the past decade.8
Figure 2 shows the many clinical manifestations of malaria
and their sequelae. Table 3 shows malaria mortality and mor-
FIGURE 1. Malaria, 2002. Source: World Health Organization, 2002.
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bidity based on an assessment of demography, transmission,
potential, and parasite prevalence. Table 4, derived from de-
mographic, clinical, and epidemiologic reports, indicates that
the mortality from malaria in Africa alone may be approach-
ing three million, almost three times the WHO estimate.5−7
One reason for the discrepancy is the WHO separation of
manifestations into direct effects and indirect effects. The di-
rect effects do not include malaria-induced acute and chronic
anemia, maternal pathology (including low-birth weight ba-
bies), hypoglycemia, and other metabolic imbalances, or long-
term neuropsychologic-developmental sequelae—all of which
contribute considerable components to the burden. In addi-
tion, the WHO calculations do not include malaria’s enhance-
ment of the severity of other childhood diseases.
The number of episodes of malaria globally has been dif-
ficult to quantify because a substantial percent of the popu-
lation in endemic areas has parasitemia at any one time and
children less than five years of age may have 4−9 or more
febrile episodes each year.4 Because rapid and precise diag-
nosis is not available in most endemic areas, WHO, UNICEF,
USAID, and individual countries advise treating febrile pa-
tients for malaria. One estimate is that outside of southern
Africa, up to 4.9 billion febrile events or anti-malarial treat-
ment exposures occur each year in Africa.5 This underscores
the critical need for reliable, rapid, simple, and inexpensive
diagnostics for malaria and other common diseases to assist ill
patients, conserve valuable drugs, and prevent emergence of
resistant parasites. Apart from the impact of malaria in chil-
dren, on pregnancy, and on anemia, hypoglycemia, acute re-
spiratory distress, and cerebral malaria dominate the pathol-
ogy. The great overlap of several clinical manifestations due
to and contributed by malaria are shown in Figure 3.9
AFRICAN LEADERSHIP IN RESEARCH AND
STRENGTHENED LINKAGES TO CONTROL
Samba highlights the new areas of research opportunity
opened by the recent sequencing of the Plasmodium falci-
parum and Anopheles gambiae genomes completed about the
same time as the full human genetic code.10 Will “detailed
knowledge of these genomes . . . lead to new drugs (vaccines,
and diagnostics)?” These fundamental advances, along with
those in functional genomics, bioinformatics, immunology,
medicinal chemistry, and pharmacology, along with improved
understanding of pathogenesis, patient management, disease
ecology and control will be most important for decreasing
malaria’s impact. We fully support the statement “African
scientists have a key role to play, in their collaboration with
their colleagues from the north and, most importantly, by
South-South collaboration.”
Ntoumi and others, all prominent African malaria re-
searchers, state that “the goals of malaria control may never
be achieved without strong involvement of those scientists
who are directly affected by this terrible disease in their daily
life” and “until recently, true participation of African scien-
tists in the international effort to control malaria has been
minimal.”11 The importance of networks to promote connec-
tion between African scientists is underscored, and inad-
equate dialogue between malaria researchers and control
managers is lamented. Managers are urged to define the con-
trol actions upon which basic and applied research can be
directed. Improved methods for monitoring resistance of
Plasmodia to drugs and Anopheles to insecticides are two
practical examples given for tying research and control to-
gether in the field. Concern is expressed about the meager
funding for African researchers compared with the problem
they face, and the fragmentation of research leadership out-
side the MIM.
THE MALARIA BURDEN: RETHINKING THE
CLINICAL AND EPIDEMIOLOGIC IMPACT
Snow and others challenge the DALY approach for quan-
tifying cause-specific health burdens.12 They state, “for ma-
laria, this categorical approach may not fully capture chronic
TABLE 2
Disability-adjusted life years (DALYs, 1,000s), all cause and malaria-related, 2002*
Population
DALYs from
all deaths (%)
DALYs from
malaria deaths (%)
DALYs from
malaria/total (%)
World 6,122,210 1,467,257 42,280 2.9
Africa 655,476 357,884 (24.4) 36,012 (85.2) 10.1
Americas 837,967 145,217 (9.9) 108 (0.2) 0.07
Eastern Mediterranean 493,091 136,221 (9.3) 2,050 (4.8) 1.5
Europe 874,178 151,223 (10.3) 20 (0.04) 0.01
Southeast Asia 1,559,810 418,844 (28.5) 3,680 (8.7) 0.9
Western Pacific 1,701,689 257,868 (17.6) 409 (1.0) 0.2
* Adapted from the World Health Organization World Health Report, 2002.
TABLE 1
Deaths and malaria-related deaths (1,000s), 2000*
Population
All deaths
(%)
Malaria deaths
(%)
Malaria/total
(%)
World 6,122,210 56,554 1,124 2.0
Africa 655,476 10,681 (18.9) 963 (85.7) 9.0
Americas 837,967 5,911 (10.5) 1 (–) 0.02
Eastern Mediterranean 493,091 4,156 (7.3) 55 (4.9) 1.3
Europe 874,178 9,703 (17.2) 0 –
Southeast Asia 1,559,810 14,467 (25.6) 95 (8.5) 0.7
Western Pacific 1,701,689 11,636 (20.6) 10 (0.9) 0
* Adapted from the World Health Organization World Health Report, 2002.
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anemia, low birth weight, and enhancement of the severity of
other childhood diseases.” In their analysis of the magnitude
to which malaria acts a risk factor for all-cause mortality in
African children less than five years of age in 48 independent
prospective studies, they found that presence of parasites in
childhood populations more than doubled all-cause mortality.
Between 1982 and 1989 mortality increased from 31 per 1,000
less than five years old with a parasite prevalence of 18% to
55 per 1,000 less than five years old with a parasite prevalence
of 95%. Between 1990 and 1999, mortality increased from 8 to
44 per 1,000 less than five years old over a range of preva-
lences of 0−95%. The beneficial effect of ITNs on entomo-
logic inoculation rates (EIRs), parasite prevalence, and mor-
tality in Kenya and elsewhere is highlighted by the investiga-
tors, and they urge “starting efforts to implement ITN
throughout Africa as a priority intervention to improve child
survival.”
Malaria-induced anemia causes more deaths than any of
the other manifestations of this disease.6 Children with he-
moglobin levels less than 11 gram percent (hematocrit < 33%)
are at particular risk and those with hemoglobin levels less
than 5 gram percent (hematocrit < 15%) require emergency
attention.13 Crawley draws attention to the myriad causes and
consequences of anemia, particularly iron deficiency and ma-
larial anemia, and the need for careful monitoring of children
for anemia starting within the first few months of life in areas
of intense and stable malaria transmission; the highest preva-
lence of anemia occurs toward the end of the child’s first
year.14 An analysis of hemoglobin levels in children in four
African countries with intense and stable transmission
TABLE 3
Malaria-related mortality and morbidity in Africa, 2000*
Condition
Total
(interquartile range)
Percent by age in years
0–4 5–14 15
Malaria-specific mortality 1,144,572† (702,957–1,605,48) 65 19 16
Maternal mortality (anemia) 5,300 – – 100
Infant mortality (pregnancy-related) 71,000–190,000 100 – –
Fatal adverse drug events 2,300 100? ? ?
Fatal HIV from blood transfusion 5,300–8,500 100 –
Epilepsy-related mortality after cerebral malaria or seizures Unknown – ? ?
Anemia, undernutrition, and HIV mortality from malaria Unknown ? ? ?
Morbidity attacks (1,000s) 213,549 (134,322–324.617) 51 35 14
Morbidity days (1,000s) 803,699 (494,416–1.298,872) 69 21 10
Neurocognitive sequelae after cerebral malaria
Hemiparesis 360–400 100 ?
Quadriparesis 770–860 100 ?
Hearing impairment 650–730 100 ?
Visual impairment 300–330 100 ?
Behavioral difficulties 1,540–1,720 100 ?
language deficits 7,000–7,800 100 ?
Epilepsy 2,700–3,000 100 ?
Effect of malaria on cognition Unknown ? ? ?
* Adapted from Snow and others.5 HIV  human immunodeficiency virus.
† World Health Report, 2002 reports 1,124,000 deaths from malaria of which 86% occur in combined “high child, high adult” and “high child, very high adult” risk areas in Africa
(http://www.who.int/whr/2002/en/whr2002_annex2.pdf).
FIGURE 2. Acute, chronic, and pregnancy-related manifestations of malaria.
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showed that > 80% of the infants 10 months of age are ane-
mic, and approximately one-third have a hemoglobin level < 8
gram percent. Anti-anemia interventions targeted to preg-
nant women and infants, and integrated into antenatal and
maternal child health care are described. Use of the
HemoCue hemoglobinometer (HemoCue, Angelholm, Swe-
den) in the field has simplified measurement of anemia, and
every hospital and health clinic with trained staff should have
access to this reliable technology. Awareness of common
causes of anemia in Africa, such as maternal and childhood
nutritional deficiencies (including micronutrients), intestinal
helminths, HIV infection, hemoglobinopathies, and malaria,
is important to manage patients and prevent the acceleration
of severe consequences of, and death from, anemia. The ma-
laria-specific interventions to prevent anemia are ITNs,
chemoprophylaxis, and intermittent preventive treatment of
pregnant women (IPT), and, possibly for infants (IPTi), and
prompt effective treatment of infections. Deworming with
mebendazole and albendazole, treatment of HIV/AIDS, in-
cluding treatment of opportunistic infections, and selective
use of iron, vitamin A, zinc, and complementary food supple-
ments should be considered, and attention given to improved
agricultural and eating practices.
Only recently has malaria’s dire effects on perinatal mor-
tality been shown. Van Geertruyden and others reviewed 117
studies published since 1948 and report that the perinatal
mortality rate (PMR) was 61.1 per 1,000 newborns in malari-
ous countries and 25.8 per 1,000 newborns in non-malarious
countries.15 Similarly, the fetal mortality rate was higher in
malaria-endemic countries. Aware of the many confounding
variables in their review, these investigators considered those
countries with a low human development index between 500
and 800; again, the PMR was much higher in malaria-endemic
countries compared with non-endemic countries. Placental
malaria was associated with a higher risk of stillbirths regard-
less of parity. The IPT of mothers and ITNs are advised to
prevent perinatal and fetal mortality from malaria.
The negative effects of co-infection with HIV and malaria
during pregnancy have now been shown definitively by ter
Kuile and others in their review of 11 studies in Africa.16
Pregnant women infected with HIV had “consistently more
peripheral and placental malaria (summary relative risk 
1.58 and 1.66, respectively), higher parasite densities, and
more febrile illnesses, severe anemia, and adverse birth out-
comes (low birth weight, prematurity, intrauterine growth re-
tardation) than HIV-uninfected women, particularly in mul-
tigravidae.” Malaria in pregnancy was increased by 5.5% and
18.8% in populations with 10% and 40% HIV prevalence,
respectively. Those pregnant women with malaria had a two-
fold higher HIV-1 viral concentration. Less clear is whether
malaria increased mother-to-child transmission of HIV.
These investigators urge more research on interactions be-
tween antiretroviral drugs, antimalarials, prophylaxis with
cotrimoxazole for opportunistic infections, and IPT, including
attention to anemia and pharmacovigilance, while strength-
ening prevention measures for malaria and HIV during preg-
nancy.
The association between malaria and undernutrition is
complex, yet improved nutrition lessens the severity of ma-
laria episodes and results in a decrease in malaria deaths.
Caulfield and others report a meta-analysis of the effect of
iron supplementation on malaria morbidity and conclude
“there was a (statistically) heightened risk of infection and
(non-significant) increase in malaria attacks and spleen en-
largement with supplementation; however, treatment was as-
sociated with significant increases in hemoglobin and de-
crease in severe anemia.”17 The investigators present their
main argument that that “deficiencies in vitamin A, zinc, iron,
folate, and other micronutrients are responsible for a substan-
tial proportion of malaria morbidity and mortality.” They
state that the attributable fraction of nutritional deficiencies
to malaria attacks in children with malaria less than five years
of age globally is 8.2 for those underweight (Z score 2), 20.1
with zinc deficiency, and 20 with vitamin A deficiency; they
ascribe the fraction of deaths in children less than five years
TABLE 4
Deaths from malaria in Africa in children less than five years of age
and total, 2001*
Cause of death
Range of deaths in
children <5 years old
Cerebral malaria 110,000 (no range)
Severe malarial anemia 190,000–974,000
Respiratory distress 110,000 (no range)
Hypoglycemia 153,000–267,000
Low birth weight 62,000–363,000
Deaths 625,000–1,824,000
All malaria deaths in Africa† 962,000–2,806,000
* Modified from Murphy and Breman.6
† Children <5 years of age represent 65% of all deaths in Africa as per Snow and others.5
FIGURE 3. Prevalence, overlap, and mortality for the major clini-
cal subgroups of severe malaria.9 Values in parentheses are the total
number of children (mean age 26.4 months) and percentages show
mortality rates. Impaired consciousness  deep coma and unable to
make a localizing response (Blantrye coma score  4); severe respi-
ratory distress  chest recession or abnormally deep breathing; se-
vere anemia  hemoglobin levels < 5 gram percent.
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old attributable to nutritional deficiencies as 57.3 for under-
weight children, 20.1 for those with zinc deficiency, and 19.5
for children with vitamin A deficiency. Caulfield and others
recommend strongly, as do other contributors to this supple-
ment, that good nutrition, micronutrient supplementation
programs, and nutrition education be integrated fully into
malaria prevention and control programs.
Important evidence is accruing of the long-term neurocog-
nitive impact of malaria following severe illness. Mung’Ala-
Odera and others point out the many limitations in extracting
such data from published studies and using demographic in-
formation to define this burden. They “estimate that at least
1,300−7,800 children will have neurologic sequelae following
cerebral malaria in stable endemic areas per year in Africa.
The figure is likely to be considerably higher, since these
estimates do not include . . . impairment following non-
cerebral malaria in children or adults . . . or populations in
low stable or epidemic areas.”18 Of 11 well-defined neurocog-
nitive sequelae following malaria (ataxia, hemiparesis/
monoparesis, severe motor deficit, dysphasia/dysarthria, be-
havioral difficulties, severe learning difficulties, visual impair-
ment, hearing impairment, cognitive impairment, language
impairment, and epilepsy), these investigators pay particular
attention to the many economic costs of disabilities due to
epilepsy and motor impairment and underscore that children
with these sequelae are prone to an early death.
Holding and Kitsao-Wekulo review direct and indirect
pathways whereby malaria can impede child development.19
They illuminate the considerable differences in methodology,
cultural context, and validation of approaches for the few
previous studies that address impaired child development fol-
lowing malaria. To overcome these differences, they suggest
applying “The International Classification of Functioning,
Disability and Health (ICF)” to such work, which covers in
great detail the subtleties and degrees of motor, cognitive,
behavioral, and other psychologic impairments that fall under
childhood development. The ICF designated outcomes, with
two-tiered division of impairment and activity limitation and
participation restriction, provide the proposed take-off point
for assessing past studies and designing new ones. With this in
view, the investigators ask the important questions, “what
should we be measuring and . . . how should we be measur-
ing it?”
THE MALARIA BURDEN: ENTOMOLOGIC AND
TRANSMISSION DYNAMICS
Establishing the relationship between transmission inten-
sity and health outcomes is crucial for the planning of long-
term malaria control programs. Unfortunately, this is fraught
with methodologic difficulties. Smith and others address some
of these difficulties by considering important parameters that
have been ignored previously. One important consideration is
that one often finds the incidence of P. falciparum infection
much lower than that predicted by the EIR, especially at
higher transmission levels.20 Their report proposes an algo-
rithm for estimating human infection rates from the EIR.
Using the algorithm, Smith and others reanalyze EIR data
and age-specific incidence of clinical malaria in two villages in
Senegal, and assess a survey of infant and child mortality rates
across Africa. The malaria transmission intensity in endemic
areas with substantial mortality appears very different from
those areas with acute morbidity. Infant mortality rates de-
crease markedly when the EIR is reduced, probably largely
because of prevention of indirect mortality. This study also
shows that reduction of exposure to malaria during infancy is
not reflected in increased mortality at older ages, a concern of
many who think that good childhood protection programs
may predispose to later susceptibility.
Killeen and others posit that comprehensive environmental
management of “mosquito resources” is a promising ap-
proach with which to control malaria but one that has seen
little application in Africa for more than half a century. A
kinetic model is presented of mosquito foraging for aquatic
habitats and vertebrate hosts that allows estimation of ma-
laria transmission intensity by defining the availability of
these resources as the rate at which individual mosquitoes
encounter and use them.21 The model captures historically
observed responses of malaria transmission to environmental
change, highlights important gaps in understanding vector
ecology, and suggests solutions. Resource availability is an
intuitive concept that provides an adaptable framework for
models of mosquito population dynamics, gene flow, and
pathogen transmission that can be defined with direct field
measurements. The model predicts that drastic reductions of
malaria transmission are possible with environmental man-
agement, and elucidates an ecologic basis for previous suc-
cesses of integrated malaria control in Africa before the ad-
vent of DDT or chloroquine. Environmental management for
malaria control requires specialist skills that are lacking in
sub-Saharan Africa where they are needed most. Infrastruc-
ture and human capacity building in clinical, public health,
and environmental disciplines should be prioritized so that
the growing financial support for tackling malaria can be
translated into truly integrated control programs.
McKenzie and Samba examine the lessons that can be
drawn from mathematical models that have long provided
important insights for malaria transmission and other infec-
tious diseases.22 They cite the recent success of the Onchocer-
ciasis Control Program in West Africa, and show that models
can make great practical contributions to intervention pro-
grams if the modeling is well-integrated into the overall plan-
ning and if the participants are clear about what models can
and cannot do.23 Their report argues that the models cannot
provide exact predictions of outcomes: they can be used to
forecast, but only in fairly gross terms. The biologic, social,
and other systems involved are sufficiently complex such that
it may not be possible to define all of the variables, much less
get precise predictions about their interactions and confident
results in a real-world situation. One must look for large dif-
ferences between different models and between different in-
terventions in the same modeling scenario. In sum, math-
ematical models can be used to 1) systematically compare
alternate intervention strategies, 2) determine the key issues
in decision-making, and 3) identify gaps in current knowl-
edge.
Using carefully collected and analyzed data from the field,
mathematical models can help focus on decisions which will
have the largest impact on outcomes and provide comprehen-
sive examination of the assumptions that enter into decisions
in a way that purely verbal reasoning and debate cannot.
Thus, models may make an important contribution to evi-
dence-based malaria control. The malaria control project in
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Garki, Nigeria in the 1970s was a test of the mathematical
models forwarded earlier by George McDonald.24,25
MALARIA IN THE URBAN, EPIDEMIC, AND
COMPLEX EMERGENCY SETTING
Reviewing evidence from Kinshasa, the capital of the
Democratic Republic of the Congo, Kazadi and others show
an unprecedented increase in the prevalence of malaria in
school age children from 1980 to 2000.26 The city has been a
perennial malarious area and has grown almost 1,400% over
43 years, from 380,000 people in 1960 to 5,293,000 in 2003.
The most complete information on malaria prevalence in Kin-
shasa was first acquired from 1981 to 1983. Blood smears were
obtained from 25,135 children (age range 5−15 years) from
245 schools in 16 of 24 zones. The mean P. falciparum parasite
rate (PR) was 17%; the PR was similar for both sexes and was
higher (P < 0.001) for older students. The PR varied from 4%
in the urban zone to 46% in the peri-urban zone. An infant
survey confirmed malaria transmission in the city because
these children had not traveled out of Kinshasa since birth.
During the Roll Back Malaria (RBM) partnership situational
analysis in 2000, malaria prevalence was reassessed by the
National Malaria Control Program and its partners in schools
from selected health zones. A mean PR of 34% was found
among school children 5−9 years of age. The PR varied from
14% in the central urban zone to 65% in the peri-urban zone.
Plasmodium falciparum was not the only species (P. malariae
was also present), but accounted for more than 97% of the
infections. Malaria incidence has increased in Kinshasa dur-
ing the last two decades due to difficulties in provision of
control and prevention measures. Along with deployment of
ITNs and improved patient management, currently ongoing,
other measures that could impact the disease are being con-
sidered, including vector control, water management, and ur-
ban planning.
Caldas de Castro and others examine malaria and its con-
trol in the urban setting. The rapid growth of cities in sub-
Saharan Africa (approximately 10% per year) is associated
with complex transformations of these specialized ecosys-
tems. Although urban malaria transmission is substantially
less intense and more focal than in rural and peri-urban set-
tings, the danger of epidemics can be higher due to the pres-
ence of non-immune populations. People of all ages are often
at comparable levels of risk in urban settings. This report
reviews the 100-year history of malaria control in Dar es Sa-
laam, Tanzania, and describes and evaluates a control pro-
gram supported by Japan that operated from 1988 to 1996.27
The investigators conclude that because of the microepide-
miology of malaria, urban risk-mapping methodology must
include high-resolution aerial photography with ground-
based validation; they contend that remote sensing technol-
ogy at a level of resolution of one meter is essential for guid-
ing intervention strategies for urban malaria control.
Keiser and others address urban malaria in general by re-
viewing the literature and using modeling. They found EIR in
cities across Africa ranging from 0 to 54 per person per year;
the EIR is dependent on the degree of urbanization, spatial
location of populations within a city, and living conditions.28
Using the latest United Nations figures on urbanization,
nighttime light, remotely sensed images, and the “Mapping
Malaria Risk in Africa” (MARA/ARMA) database, with its
findings on climate suitability for stable malaria transmission,
these investigators estimated that 200 million people (24.6%
of the total African population) currently live in urban set-
tings where they are at risk of contracting the disease.29 This
is cause for great concern in that the surface area covered by
these urban settings is approximately 1.1−1.6% of the total
African surface. Using different scenarios, Keiser and others
estimate an annual incidence of 24.8−103.2 million cases of
clinical malaria attacks among urban dwellers in Africa.
These figures translate to 6−28% of the estimated global an-
nual disease incidence. Mitigation of the current burden of
malaria in urban African settings with visionary planning is
necessary for environmentally and socially sustainable devel-
opment. It appears that urban malaria control will be more
cost-effective than in rural areas, and research is needed to
confirm this.
Malaria epidemics have been on the increase during the last
10 years. Kiszewski and Teklehaimanot discuss this phenom-
enon, which results from special interactions between vectors,
parasites, humans, and various environmental and anthropo-
genic determinants.30 Figure 4 shows particularly vulnerable
areas of Africa against a background of different levels of
endemicity.5,31 The explosiveness of malaria epidemics al-
ways strains the capacity of health facilities, causing case fa-
tality rates to increase five-fold or more during outbreaks.
People of all ages remain susceptible to the full range of
clinical effects. The disease profile always has major eco-
nomic consequences, although the full economic impact of
FIGURE 4. Malaria risk areas in Africa according to climate suit-
ability.5,31 White  class 1, no transmission; yellow  class 2, mar-
ginal risks, uncommon transmission in an average year; orange 
class 3, acute seasonal transmission with a tendency toward epidem-
ics; brown  class 4, stable endemic transmission.
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epidemic malaria remains undefined. Specialized intervention
approaches are needed for epidemic-prone areas, including
enhanced surveillance activities and intensified antivector in-
terventions. Such considerations are particularly critical at a
time when malaria epidemics are occurring more frequently
in Africa and throughout the world.
Worrall and others review malaria epidemics and the dif-
ficulties of estimating their economic burden.32 The main
problems are the lack of a sound understanding of the epide-
miologic toll and imprecision of the economic impact of ma-
laria epidemics at all levels of the economy. There is no recent
evidence from Africa on the macroeconomic impact of ma-
laria epidemics. Examples are from the private sector and
cover epidemics in the highland tea and coffee estates in east
Africa; unfortunately, the impact on the companies’ produc-
tivity, profitability, and growth remains unquantified. Work
has begun to examine the cost of recent malaria epidemics in
a sugar estate and orange plantation in Ethiopia (Ministry of
Health of Ethiopia). In the public sector, epidemics may im-
pose large political and opportunity costs on governments
that often divert funds from other areas (usually within the
health sector) to deal with large-scale epidemic emergencies.
A 1996−1997 malaria epidemic in one district of Zimbabwe
was estimated to add approximately $290,000 to the direct
costs of malaria control to the Ministry of Health alone, when
compared with costs in the prior, non-epidemic year. Aside
from this rough estimate, the direct and indirect costs which
malaria epidemics impose on governments remain an impor-
tant area for investigation.
THE MALARIA BURDEN: ECONOMIC AND
SOCIAL IMPACT
Despite imprecisions, the malaria toll has been relatively
well-quantified clinically and epidemiologically. In economic
and social terms, it is less well understood. The channels by
which disease lowers gross domestic product per capita is
shown in Figure 5.33 Estimates have suggested that malaria
costs the African countries $12 billion annually and may con-
siderably retard economic development.34 An African family
may spend up to 25% of their income on malaria prevention
and control.35 The economic burden of ill health on individual
households can be substantial and in some cases catastrophic,
especially for poor households. Russell reviews studies that
have measured the economic costs and consequences of ill-
ness for households, focusing on malaria, tuberculosis and
HIV/AIDS.36 He finds that illness imposes high and regres-
sive cost burdens on patients and their families in poor set-
tings. Health service weaknesses contribute to these high
costs in many countries, and include low coverage, user
charges, and poor quality of care. Solutions lie in expanded
access to high quality, carefully supervised preventive and
curative health services.
FIGURE 5. Impact of disease on lowering gross domestic product (GDP) per capita.33
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Malaney and others state “although the correlation be-
tween malaria and poverty is apparent, the nature of the link-
ages in terms of directions and causation is less so, and dif-
ferent methodologic approaches provide widely divergent
perspectives.”37 They review the evidence on both the mac-
roeconomic and microeconomic impact and seek to explain
why the former provides estimates of burden that are much
greater than the latter. They argue that the economic exter-
nalities associated with malaria make the burden much
greater than the sum of the costs of individual cases. For
example, if malaria affects schooling decisions of households,
then this could change long-term income streams in a much
more marked fashion than would be expected from a case-
by-case analysis of costs.
Jones and Williams point out that epidemiologists and
economists have dominated the burden literature. They attest
that culture, beliefs, and political context affect perceptions,
individual behaviors, social structure, and social action.38 It is
important to understand the social burden, or the process
through which social and cultural factors affect the biomedi-
cal burden of malaria. Society’s perceptions of disease, ma-
laria, and perceived risk influence people’s willingness to
change their health behaviors, but the political and economic
context, social organization, and cultural rules affect their
ability to change behavior. Recently, the concept of social
vulnerability has been developed to highlight the importance
of social factors that make some groups or individuals more
susceptible to infection or more vulnerable to the conse-
quences of infection. For example, women may be limited in
their access to cash and ability to take decisions on their own,
affecting their ability to seek treatment of a sick child. The
investigators argue that understanding the sociocultural di-
mensions of the burden of malaria is vital to development of
interventions to access vulnerable groups.
HEALTH SYSTEMS AND THE MALARIA BURDEN
Health management information systems (HMIS) includ-
ing routine surveillance systems at health facilities provide the
immediately visible evidence of the burden of malaria, which
is the basis for planning. Most malaria-related morbidity is
treated at home and within the community by informal health
services and networks. Ageypong and Kangeya-Kayondo use
a case study from a rural district in Ghana to illustrate the
wide difference between estimates of the burden of “febrile
illness presumed malaria” based on routine HMIS data, and
that derived from community level data on morbidity and
health seeking behavior of households.39 For every patient
with febrile illness seen in facilities, there were 4−5 such epi-
sodes in the community. Given the urgency of changing drug
use policies in Africa, and exploring associated costs and lo-
gistics, it is urgent that better and more timely data on burden
be available to health service planners. The report by Agye-
pong and Kengeya-Kayondo highlights the current practices
of treatment-seeking families, indicating how much self-
treatment through purchase of drugs occurs. These practices,
widespread in most malarious countries, raise questions on
what should be the appropriate policy response.
Who should pay for malaria interventions? Hanson out-
lines how the tools of economic analysis can contribute to
such discussions. She argues that there are powerful economic
arguments to support public action to increase the uptake of
effective malaria interventions.40 Market failures are likely to
arise from the monopoly power of pharmaceutical firms. An-
other important form of market failure arises from “exter-
nalities,” which are benefits or costs of consumption or pro-
duction that are not fully valued by the consumer/producer.
As a result, the level of consumption is often not optimal.
Externalities affect, for example, availability and deployment
of ITNs, residual insecticide house spraying, environmental
control, and, potentially, artemisinin-based combination
therapy (ACT). Commercial markets are unlikely to guaran-
tee adequate uptake of interventions where there is wide-
spread poverty. Limited public resources mean that prioriti-
zation is necessary. Economic analyses help decision making
by setting priorities through cost-effectiveness analyses, un-
derstanding how markets for interventions operate, and the
extent to which different approaches reach the poor, the
prime target of public actions.
A recent and very important theme in research and policy
debates has been the impact of malaria on different socioeco-
nomic groups and the extent to which the poor are reached by
interventions. Barat and others report that malaria dispropor-
tionately affects poor countries, with 58% of the cases occur-
ring in the poorest 20% of the world’s population.41 Within
countries, there is contradictory evidence on whether the
poorest experience more febrile episodes, and quite strong
evidence that the severe consequences of malaria are borne
most heavily by the poorest citizens. These investigators call
for more research on financial and non-financial factors that
limit the accessibility and use of malaria control services by
the poorest, who remain the most vulnerable persons.
INTERVENTIONS: ACT
While CQ and sulfadoxine-pyrimethamine (SP), are be-
coming increasingly ineffective throughout the world, most
recently in Africa, they are still being used, particularly in
western Africa. Yeung and others advocate the use of ACT
“for delaying the development of resistance to the remaining
armory of effective drugs.”42 Combination drug strategy is
used for tuberculosis, HIV infection, and cancers. The inves-
tigators outline the difficulties in measuring the burden due to
parasite resistance to drugs and in defining the impact of
control strategies. They use a mathematical model to address
these and other issues tied to policy options in the face of drug
resistance. A major impediment to using ACT is its cost, cur-
rently $1.20−2.50 per adult treatment compared with
$0.10−0.20 per adult treatment for CQ and SP. The cost-
effectiveness model presented by the investigators uses bio-
logic and economic information. They assume that the demise
of CQ has contributed directly to the doubling of malaria-
specific mortality over the last 15 years.43 The investigators
urge that patients in drug-resistance studies be followed for 28
days rather than 7 or 14 days as recommended by the WHO.
This should now be easier with the availability of parasite
genotyping, allowing researchers to distinguish between re-
crudescence and reinfection. The genetic basis of resistance is
described fully by these investigators who state “for resistance
to spread the spontaneous occurrence of a mutation . . . is not
sufficient”. Drug pressure is necessary to confer survival ad-
vantage of resistant parasites. To date, resistance to artemisi-
nins has not been documented.
CONQUERING THE INTOLERABLE BURDEN OF MALARIA 9
Using ACT, preventing spread of resistant parasites opti-
mally requires a three-day treatment; monotherapy with ar-
temisin compounds requires seven days of treatment. Drugs
with a long half-life allow longer parasitic exposure to sub-
therapeutic drug levels. Under these conditions, drug resis-
tance mutations are more likely to develop and spread. Ye-
ung and others make a strong plea for accurate diagnosis
before treatment, using rapid diagnostic tests.42 They admit
that these tests are costly ($0.70 per test) and likely to be most
cost-effective when more than 50% of the patient population
is parasitemic; these dip-stick enzymatic tests have other ad-
vantages and disadvantages when compared with micros-
copy.44 Artemether-lumefantrine (Coartem; Novartis,
Basel, Switzerland) is the only registered ACT; however, di-
hydroartemisinin-piperaquine (Artekin; Chongqing Holley
Holding, Chongqing, People’s Republic of China) has been
found to be safe, effective, and acceptable, and is cheaper
than Coartem. Although Artekin® is used extensively in
Cambodia, China, and Vietnam, this drug has not yet gone
through the lengthy regulatory process required for interna-
tional use. The model used by these investigators incorpo-
rates drug, epidemiologic, parasitologic, vectorial, behavioral,
and economic factors. It is a time-intensive model in which
drug resistance develops in two stages: de novo and with sub-
sequent spread. Studies have shown that patients with meflo-
quine-resistant parasites carried gametocytes four times
longer than those with sensitive parasites.45 A relative repro-
ductive rate of four for resistant infections is used in the
model. The increasing cost of drugs with increasing drug re-
sistance and other costs, e.g., consultation, diagnosis, inpa-
tient care, and specific complications (anemia, cerebral ma-
laria, renal failure, and low-birth weight babies) are consid-
ered in the model as are transport, food, medicines, and loss
of productivity.
Laxminaryan also uses a bioeconomic model of malaria and
evolution of drug resistance to examine ACT and the eco-
nomics of dealing with drug resistance.46 His focus is on the
economic evaluation of alternatives to use of CQ. Sulfadox-
ine-pyrimethamine has the advantage of requiring one dose,
costs approximately one-tenth as much as ACT, and is ap-
proved for use in children and pregnant women; the disad-
vantage is that parasite resistance to SP is expected to in-
crease. The use of ACT will delay resistance and offer faster
and higher cure rates than other drugs. Laxminaryan models
replacement of CQ with 1) ACT and 2) SP with waiting for
resistance to develop before using ACT; optimal coverage is
also considered. He echoes Yeung and others in stating that
“resistant strains face an evolutionary disadvantage in the
absence of antimalarials.” Both Laxminaryan and Yeung and
others posit that effective treatment is associated with loss of
immunity, but there is little evidence for loss of protective
immunity after treatment in the African milieu. It is true that
the use of ACT or other effective treatments will reduce the
number of parasites in circulation by reducing the duration of
illness.
One artemisin model is based on the questionable assump-
tion of Laxminarayan that malaria-specific mortality would
be zero. This needs further elaboration, despite the statement
that “introducing an appropriate case fatality rate did not
alter the results relatively.” Laxminarayan concludes that, in
the short run, SP may be preferable at low and high levels of
coverage and low selection pressure. However, at high levels
of treatment coverage, resistance will evolve rapidly. For
long-range planning, a direct switch to ACT is desirable given
the high morbidity associated with increasing resistance to SP.
The contention that “with higher intensity of transmission,
the benefit . . . of ACTs . . . is diminished because of greater
immunity associated with transmission . . .” remains to be
proven. The model shows that the economic advantages of
introducing ACT immediately are lower for situations with
high frequencies of resistance to either drug in the ACT. In
addition, patients taking three doses of ACT will be less ad-
herent to taking the complete treatment than those taking
one dose of SP, which could theoretically expedite resistance
to the components of the ACT.
Coleman and others use a decision-tree model to estimate
the incremental cost-effectiveness of using ACTs, compared
with current therapies over 5-, 10-, and 15-year periods.47
Defining the growth rate of ACT resistance to other drugs
allows calculations of the threshold ratio at which ACT is no
longer cost-effective, compared with any levels of resistance
to current therapies including the starting levels of resistance
following monotherapy. By their model, these investigators
show that ACT is more than 95% likely to be cost-effective
over any time period under most conditions other than with
very low levels of initial resistance to CQ, and over a five-year
time frame. They focus on 1) the growth rate of resistance of
ACT relative to monotherapy, and 2) the starting level of
resistance of the monotherapy. Comparisons are made of the
cost-effectiveness of ACT relative to a baseline scenario of
retaining SP over a set time period. The investigators restrict
the analysis to true malaria and weight the population by the
proportion <5 years of age and 5 years of age. As for the
other models, compliance is a major factor in the analysis as
is proportion of resistant parasites and probability that the
treatment is effective with partial compliance. The model al-
lows DALYs and costs to be calculated. Policy change costs,
which can be substantial, are not factored into this model, or
in the others. The incremental cost-effectiveness ratio is com-
pared with a cut-off value of $150 per DALY averted, “a
rough economic criterion by which a health intervention in a
developing country may be judged . . . attractive.” Above
60% resistance to SP, ACT is cost-effective for a 10-year
period. The investigators present a very elegant analysis of
the economic effectiveness of ACT over different time peri-
ods, and different levels of drug resistance. The advantages of
ACT over SP, with the latter drug having 20−60% resistance,
are highlighted depending on the time frame (5, 10, or 15
years). These investigators conclude rightfully that “given
current limited production of ACTs, . . . logistical support
must be in place to ensure that ACT is widely available before
advocating a switch in policy.”
One important economic assumption regarding ACT use is
that direct costs such as drugs, consultations, and laboratory
testing amount to approximately 20% of the costs, with op-
portunity costs of travel and loss of productive time, totaling
1−5 days per patient, comprising 80% of the costs. For ex-
ample, a study in four African countries (Burkina Faso, Chad,
Republic of the Congo [Brazzaville], and Rwanda) found that
a case of malaria costs $9.83 (in 1987 dollars) of which 19%
was direct costs (treatment and control) and 81% indirect
costs (morbidity, mortality and economic losses).48 Since the
average value of goods and services produced per day in Af-
rica was $0.82, this cost was equivalent to 12 days of output.
BREMAN AND OTHERS10
Although the costs of drugs are only a small percentage of the
economic cost of a malaria episode, the likely increased use of
ACT will lead to major expenditures. Between $1.6 and $3.4
billion per year will be required for African countries to have
malaria treatment policies based on ACT.49
INTERVENTIONS: MONITORING, EFFECTIVENESS,
AND COST-EFFECTIVENESS
For disease control, the balance between an intervention-
specific approach and a broad health services approach has
been debated over many decades, with the pendulum swing-
ing from one period to another. Following the failure of ver-
tical malaria control programs to achieve eradication during
the 1960s and 1970s, the World Health Assembly in 1985
adopted a resolution recommending that malaria control ac-
tivities be developed as an integral part of primary health care
systems at the district level. Alilio and others assess the extent
to which primary health care services contributed to reducing
the burden of malaria in one district in Tanzania between
1996 and 2003. They find an unchanged malaria burden since
the 1960s and limited effectiveness of district health services
in controlling malaria.50 Although there had been a process of
decentralization, the district management had weak capacity
to develop and implement local policies and received little
training on malaria control; organizational and other changes
did not result in better operational decisions, improved access
to treatment, or fewer malaria cases and deaths. The investi-
gators recommend that a combination of central (national)
and local action is required for effective malaria control, and
that activities at the district level require better coordination
and definition. The evaluation of effectiveness of district ac-
tions using longitudinal data and an in-depth case study ap-
proach is advised.
An alternative methodologic approach is taken by Over
and others in analyzing the contribution of a mix of interven-
tions to malaria control in the Solomon Islands from 1993 to
1999.51 To determine the contribution of each method, data
were analyzed by monthly incidence and by assessing control
activities for 41 of 110 malaria zones. The analysis found that
spraying with DDT, use of ITNs, and education on malaria
were all independently associated with reduction in malaria
or fever incidence, while larviciding with temephos was not.
The use of treated nets permitted a reduction in DDT spray-
ing, but would not replace it without substantially increased
malaria incidence.
de Savigny and Binka examine problems in measuring the
impact of the malaria burden in sub-Saharan Africa. They
argue that ambitious new goals for control of malaria have
been set and significant additional resources for malaria con-
trol are being mobilized. Yet, for many of the countries most
severely burdened by malaria, baseline data and reliable
monitoring of key impact indicators are lacking.52 For such
countries, it will be difficult to know when targets are met or
whether to make mid-course corrections if progress is inad-
equate. The new investments in malaria control have trig-
gered a resurgence in the demand for health information for
assessment of performance-based resource allocation. Activ-
ity (process) and health impact (outcome) indicators need to
be defined early, with clear goals and milestones to track
local, national, and international achievements.53 It is essen-
tial to support more integrated information systems able to
monitor change and guide approaches, not just for malaria,
but for other important health and poverty-related interven-
tions. The investigators urge re-thinking the nature of the
data and the sources feeding into the management informa-
tion systems in resource-poor settings. They suggest a path-
way that helps create effective monitoring and evaluation sys-
tems in a framework for longitudinal, iterative, and evidence-
based decision making. Health information systems of the
future will need much greater coherence in using information
from disparate sources and much greater ability to influence
punctual actions in the field.
Monasch and others add to the issues raised in the report
by de Savigny and Binka by examining childhood coverage
with mosquito nets and malaria treatment. This report, based
on population-based surveys in African countries, provides a
useful baseline for monitoring progress in the RBM partner-
ship. Data are reviewed from 23 Multiple Indicator Cluster
Surveys and 12 demographic and health surveys (DHS) con-
ducted between 1998 and 2002.54 The investigators examine
the proportion of febrile children less than five years of age
with prompt effective antimalarial treatment and the propor-
tion of those less than five years old sleeping under ITNs or
any mosquito net the preceding night. A median of 53% of
the febrile children received antimalarial treatment; a median
of 84% of these treatments used CQ. The proportion of treat-
ments given within two days of onset of symptoms was un-
known in most surveys. Median coverages of those less than
five years old with any net and with ITNs was 15% and 2%,
respectively. Use of nets, and especially ITNs, was consis-
tently lower in rural than in urban areas. At the outset of
intensified malaria control under the RBM partnership, cov-
erage with principal interventions was minuscule, far below
the target of 60% set for Africa in 2005. Much remains to be
done to improve effective coverage for effective treatment of
and protection from malaria. Measuring change accurately
and frequently, and taking action, is a challenge of great ur-
gency and magnitude and merits the highest priority.
WHAT’S NEEDED: RESEARCH, TRAINING,
AND CONNECTIVITY
Great progress has been made in development of vaccines
for malaria. Ballou and others report that there are now 35
candidate malaria vaccines in clinical development, many of
which are, or soon to be in clinical trials.55 Of these, the
pre-erythrocytic vaccines that target sporozoites or schizont-
infected liver cells, preventing the release of primary mero-
zoites from infected hepatocytes, have received the most at-
tention; 16 candidate vaccines are in this group. While only a
100% protective response translates into sterile immunity for
a vaccine directed against this stage of the parasite, responses
that are 80−90% effective may delay onset of patent para-
sitemia and elicit an eight-fold reduction in circulating infec-
tious sporozoites. These investigators report that the RTS,
S/AS02A vaccine, based on the circumsporozite protein of
the 3D7 clone of P. falciparum, showed some protection in
humans over two transmission seasons, including reduction of
febrile malaria attacks. It is crucial to formulate the vaccine
with the proprietary adjuvant AS02A. The formulation stimu-
lates Th-1 cellular immune responses, which were shown to
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be important in clinical trials. The protective immunity con-
ferred by this vaccine wanes over time. The RTS, S/AS02A
vaccine development and testing is an excellent example of
private-foundation-public partnership, in that Glaxo-Smith-
Kline Bio, the Malaria Vaccine Initiative (supported by the
Bill & Melinda Gates Foundation), and governments in Gam-
bia, Mozambique, and elsewhere are partners in its testing.
The target for the 15 candidate asexual stage vaccines is the
merozoite, initially released from infected hepatocytes, which
rapidly enter circulating red blood cells. The complex process
of merozoite invasion of red blood cells requires contact, ad-
herence, and orientation to the cell-wall membrane, and in-
volves numerous parasite proteins located on the surface of
the merozoite and targeted by circulating antibodies. Mero-
zoite surface protein 1 (MSP-1), MSP-2, MSP-3, and apical
menbrane antigen 1 are the most studied asexual stage vac-
cine antigens. Although antibodies directed against the para-
site are essential, cell-mediated mechanisms are critical for
acquired immunity. Variability in parasite genetic composi-
tion is a major hurdle in development of blood-stage vaccines.
Production of antibodies against the carboxy-terminal portion
of MSP-1 has been achieved and the antigen adjuvantized as
falciparum merozoite protein-1/AS02A. A trial of this vaccine
in children is scheduled in western Kenya.
Antibodies directed against several sexual parasite stage
antigens can prevent infectious sporozoite development in the
salivary glands of Anopheles mosquitoes. These transmission-
blocking vaccines (TBVs) have received much-deserved in-
creased attention over the past 10 years and two antigens are
in development. The TBVs do not protect individuals receiv-
ing them from malaria infections. High coverage with an ef-
fective vaccine will be needed to stop malaria transmission.
This is why TBVs are called the “altruistic” vaccines. Sexual
stage antigens have proven to be complex proteins with com-
plex folding requirements and formulation of immunogenic
vaccines remains a challenge. Plasmodium vivax antigen
Pvs25 produced in Saccharomyces cerevisiae elicits antibodies
in mice, rabbits, and non-human primates and blocks trans-
mission in membrane feeding assays. Plasmodium falciparum
antigen Pfs25 expressed in Pichia pastoris appears promising.
Another very intriguing approach is to irradiate large num-
bers of sporozoites, effectively producing a killed parasite
asexual-stage vaccine. This revisiting of work begun 30 years
ago merits increased attention.56
The key to success in malaria vaccine development will be
increased funding and support by public-private partnerships,
particularly for production of test lot vaccines by good manu-
facturing procedures and conducting phase 1 and 2 studies. It
is very encouraging that RTS, S/AS02A, modified vaccine
Ankara−multi-epitope thrombospondin-related adhesive
protein (MVA-ME TRAP), and MSP-1/AS02A vaccines are
now being tested in pediatric populations in malarious set-
tings, the most vulnerable group. One of the greatest needs
that is sure to increase over the next several years is for more
qualified clinical investigators in malaria-endemic and non-
endemic countries to carry out the vaccine studies.
The major decisions for introducing malaria vaccines and
other new or improved interventions to control malaria into a
country will be made by national policy makers. These per-
sons must use the results of research wisely to minimize de-
lays and get the most benefit once a malaria vaccine is ready
for use. Moree and Ewart review the factors to consider for
rational decision-making when introducing a malaria vac-
cine.57 These are disease burden, economic burden, cost-
effectiveness of existing anti-malaria interventions, financing
plans, delivery and infrastructure systems, and the selection of
specific new vaccines, malaria and otherwise. Key decisions
will depend upon a vaccine’s ability to reduce morbidity and
mortality and competing demands for funding. To illustrate
the decision-making process, these investigators assume a
30−50% vaccine efficacy for one year in preventing severe
disease in children 1−4 years of age, with three doses required
at $10 per dose. They cite hepatitis B and Haemophilus in-
fluenzae type B experiences to illustrate how long delays in
vaccine deployment can occur despite proven efficacy, par-
ticularly in low-income countries. Modeling can be useful to
inform vaccine outcomes, particularly when surveillance is
poor. AMANET, formerly the African Malaria Vaccine Test-
ing Network (AMVTN), has promoted the collection of epi-
demiologic data on malaria to support vaccine trials. Demo-
graphic and Surveillance Surveys are tracking malaria and
other diseases over a longer period in large populations as is
the International Network of Field Sites With Continuous
Demographic Evaluation of Populations and their Health in
Developing Countries (INDEPTH) and other DHS activities.
Major constraints to timely introduction of a malaria vaccine
could be the regulatory process. Regulatory reviews, impor-
tant as they are, cost time and money and affect manufactur-
ing and delivery of a sorely needed intervention. Operations
research should focus on demographic and epidemiologic in-
formation and include accurate measurement of the disease
and economic burdens, and cost-effectiveness of interven-
tions, using modeling.
Despite the urgent need, Ijumba and Kitua attest that
“. . . there are still no significant initiatives for strengthening
capacity for malaria control through training within the Af-
rican continent. . . .”58 In Tanzania, where these investigators
live and work, the Center for Enhancement of Effective Ma-
laria Interventions (CEEMI) has been established. The
CEEMI will help “to provide . . . skills for identifying and
solving problems and providing incentives to malaria control
workers in their work performance.” Their report describes
the workforce needs to achieve the goals of RBM, the main
goal being decreasing the burden of disease by 2010. They
state that “the targets will not be met until governments
honor their (Abuja) pledges, sufficient funds are generated at
the global level and . . . activities at district, country, and re-
gional levels are strengthened sufficiently. . . .” Impediments
to proper use of human resources are shortage of skilled
workers, misuse of time, poor mentoring, lack of focus on
specific problems, and diversion of malaria control staff to
other health issues. Current training is centered on easy ad-
vancement and personal gain rather than on capacity
strengthening. It produces certificate holders, not committed
leaders or implementers. The CEEMI is part of the Gates
Malaria Partnership that links the London School of Hygiene
and Tropical Medicine with two northern and five southern
partners in four malaria-endemic countries (Gambia, Ghana,
Malawi, and Tanzania). The partnership roles are “to
strengthen research capabilities and augment existing capac-
ity through establishment of training centers in African-
partner countries . . .” and “for transferring knowledge (and)
strategies related to (putting) malaria control into action.”
The investigators stress the importance of defining training
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needs, goals, strategies and actions, and monitoring and
evaluation; the latter is a greatly neglected area. They envi-
sion the CEEMI as a place to support innovations for train-
ing, and will include training in the conduct of operational
research, evaluation, and documentation.
A novel approach at CEEMI is that the candidates will
define their work plan with local health and administrative
officials before they come for training. In this way, the train-
ing modules can be tailored to the specific needs of the train-
ees and their districts. The major components of the Tanza-
nian National Malaria Control Program are case manage-
ment, vector control with ITNs, prevention of malaria in
pregnancy, and epidemic preparedness and prevention. It is
expected that similar approaches in the Gambia, Ghana, and
Malawi will allow mutually beneficial feedback through fre-
quent exchanges of curricula, participants, teachers, and
shared evaluations. An early workshop sponsored by CEEMI
focused on ethics, information retrieval from the Internet,
and traditional malariology. An e-mail discussion group was
established to ensure that dialogue between participants and
trainers continues long after the course completion.
Improved communication and coordination with colleagues
by African scientists working on malaria has been the mission
of the Multilateral Initiative on Malaria Communications
Project (MIMCom). Royall and others report that over the
past seven years MIMCom has supported full access to the
Internet and resources of the World Wide Web at 19 research
sites in 10 countries.59 MIMCom has two websites: one is
linked to resources, databases, and a document delivery ser-
vice for full-text journal articles; another site is research
agenda-specific, with a server capable of sharing data be-
tween members of MIM networks concentrating on a specific
research theme. The key to the success of this very original
activity has been the fact it was conceived by African re-
searchers and, with them, designed, implemented, and moni-
tored closely by the U.S. National Library of Medicine
(NLM). Support from a variety of national and international
collaborators, with expertise in information technology, sat-
ellite access, data management, local telecommunications, lo-
cal regulations, and financial stability has been the sine qua
non of MIMCom. The project focused first on taking advan-
tage of the NLM decision to make MEDLINE available free
to the networked world in 1997, the time MIM began. The
key question asked by MIMCom of the African scientists was
“what is it that researchers are trying to accomplish but can’t,
given current telecommunications access?” The focus is en-
tirely on local needs and priorities, cost-effectiveness, and
local responsibility. An evaluation team focuses on local tele-
communications availability to gain access to the World Wide
Web, sending e-mail and large data files, and downloading
large documents. When not available and needed locally,
MIMCom uses satellite, microwave, or other wireless options.
This includes a Very Small Aperture Terminal (VSAT) sys-
tem in Kenya using a technical hub in the United Kingdom
linked to a geostationary communications satellite 22,000
miles above the Atlantic Ocean. As new research stations
have joined the VSAT system, costs are decreased by group
purchases. Another special feature of MIMCom is that the
equipment supplier has provided a unique bandwidth shared
by more than 1,000 scientists and their support teams. At each
site, there is a List Server, Help Desk, Intranet, written usage
policy with tools to monitor usage, and tools to block unre-
lated websites. These innovations promote creative local
problem solving and conserve valuable telecommunications
resources.
MIMCom has held a series of meetings to share research
and telecommunications activities and experiences with net-
work numbers. During these exchanges researchers from dif-
ferent countries and sites developed a memorandum of un-
derstanding covering their collaboration, data sharing, data-
base security, publication policies, development of a website,
and defined the responsibilities of each investigator for the
website pages. The shared funding of the project locally helps
to ensure sustainability and ownership by a larger number of
parties rather than the fragility created when only one donor
or northern scientific laboratory carries the entire project.
The comment by one African colleague about the benefit of
MIMCom is revealing “. . . we (now) run projects in Africa,
we forward mail to each other, we plan and agree and dis-
agree. It is not one man writing a letter (to us), giving instruc-
tions. There is a difference here. It is a completely different
way of communicating.”
CONQUERING MALARIA:
INTERNATIONAL ACTIONS
International action in malaria research and control has a
long history. Alilio and others identify three decades of great
optimism after 1949. Successes in largely temperate or sub-
tropical areas occurred where transmission was unstable and
engendered undue expectations for malaria control else-
where. Unfortunately, early successes led to substantially de-
creased support for research; on the control side, the disillu-
sionment that followed the failure of eradication was followed
by several decades of neglect of malaria in international
health policy debates.60 These investigators review this his-
tory of multilateral malaria research and control programs in
Africa to discern lessons to inform multilateralism and dem-
onstrate the need to link research and control closely. Al-
though the proliferation of malaria control programs in the
late 1990s has brought substantial additional funds and ex-
pertise, it raises considerable concerns over duplication and
coordination. They propose an umbrella malaria coordinating
group to ensure inclusiveness, sharing of agendas, goals, and
achievements, and increase advocacy for malaria research
and control.
The MIM represents one of the most successful recent ma-
laria initiatives; it has an explicit networking aim through
linking and supporting organizations and individuals con-
cerned with malaria research. It focuses on maximizing the
impact of scientific research on malaria control in Africa
through the promotion of research capacity building and fa-
cilitation of global collaboration and coordination. Heddini
and others review the experience of MIM since it was created
in 1997, and comment on its current components, activities,
and future challenges. Their report underscores the impor-
tance of the MIM Alliance as a coordinating device, and em-
phasizes the need to retain research capacity strengthening as
its prime focus.61 The research grant component of MIM has
awarded funds to more than 23 African scientific groups. The
scientists collaborate with a northern institution and, where
possible, with one or more other African institutions. The
Tropical Disease Research Program of WHO manages this
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component of MIM. The Malaria Research and Reference
Reagent Resource Center (MR4), supported by NIAID, col-
lects and distributes biologic materials for malaria research
and does training. The MIM will continue to expand its focus,
with more consideration of P. vivax and malaria in Asia and
the Americas and strengthening of the research and control
interface.
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